Blog

Come See ACS at AAPM Booth 1! March 7-10, 2024

AAPM_Event.png

The Association of Cannabinoid Specialists will be active at the American Academy of Pain Medicine's 40th Annual Meeting in Scottsdale, AZ from March 7-10, 2024.  Come talk to us, learn from us, and join us as we work toward making cannabis a mainstream pain management option.

  • Come See ACS at AAPM Booth 1! March 7-10, 2024

    AAPM_Event.png

    The Association of Cannabinoid Specialists will be active at the American Academy of Pain Medicine's 40th Annual Meeting in Scottsdale, AZ from March 7-10, 2024.  Come talk to us, learn from us, and join us as we work toward making cannabis a mainstream pain management option.

  • Cannabis and Heart Disease: What Do We Really Know?

    Heart_disease.png

    This week there has been a flurry of discussion about cannabis’ harmful effects on the heart.  I have received numerous anxiety-ridden emails from colleagues, patients, and my mother (she’s not on cannabis, go figure).  This all stems from a recently published scientific paper in the Journal of the American Heart Association. (1)

  • Member Spotlight: Sandra Carrillo, MD, MHSM

    Sandra Carrillo

    Q: Tell us a little bit about yourself.

    A: My name is Sandra Carrillo, and I am a medical doctor. I have had a clinical practice in Colombia for several years.  I am a specialist in cannabinoid-based medicine.

  • ACS Guidance to Massachusetts on Veteran Care

    veteran_at_doctor_office.png

    Dear Members of the Joint Committee:

    As one of the senior cannabis physicians in the Commonwealth of Massachusetts, President of the Association of Cannabis Specialists, Board Member of the Massachusetts Patient Advocacy Alliance, and former VA physician I wish to convey some very specific concerns regarding House Bill 4274. Despite vocal advocacy by a few veterans, this bill is not in the interests of veterans or other patients.

  • ACS Response to JAMA article entitled Most Doctors Know Nothing About Cannabis

    doctor_studying_(1).png

    In an editorial in JAMA (date), Dr. Nathaniel Morris, a recent Stanford graduate, laments that even in California where medical cannabis has been available since 1996, no medical education on cannabis was provided to him during medical school or residency.

  • ACS Response to Oil (Vape) Pen Ban

    group_of_vapes.png

    The currently posed question of when or whether the embargoed oil cartridges can be released for sale has at least two separate issues embedded. First is the question of the safety of these particular cartridges, and the second is the safety of any such cartridges that use current technology. Both of these questions would reasonably need to be affirmed prior to sales.

  • Prescription Vs. Recommendation

    RX.png

    Since the inception of medical cannabis legalization in California in 1996, physicians have only been able to write a “recommendation”. This was intended, at that time, to keep the practitioners out of trouble with the government by providing only a document stating that the benefits likely outweighed the risks. 

  • ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines

    MCRAA.png

    The Medical Cannabis Research Advocacy Alliance (MCRAA) appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry; Availability 85 FR 44305 (July 22, 2020).

  • ACS Takes Issue with Wall Street Journal Advertisement

    Wall_street_journal.png

    To Whom It May Concern at the Wall Street Journal:

    We write to you to express a concern over a recent ½ page advertisement in the Journal.

  • ACS Letter To ONDCP Director Rahul Gupta

    Office_of_national_drug_policy_control.png

    Dear Dr. Gupta:

    Congratulations on the confirmation as Director of the Office of National Drug Control Policy. We welcome your leadership as our respective agendas are to improve and serve the health of the American people.